I am Bruno Paiva from the University of Nevada in Pamplona, Spain, and at ASH we are presenting for the first time ever the initial analysis on the first 1000 patients enrolled in the No More MGUS project.
The No More MGUS project is probably the craziest project that we have ever launched. A towel exhibition and laboratory. Probably one of the biggest ones seen it is Spain, and even at the European level. In fact, I take this opportunity to invite everyone that might be listening, to participate and also to support the project.
We aim to enrolling 5000 MGUS cases. We have currently enrolled 2000. And we are presenting data on the first 1000. And we are studying these individuals with MGUS every year during five years, meaning 25,000 samples, approximately a massive, massive project.
Our aim is to change the name of MGUS into some extent by defining bundle clinical gammopathy of no clinical significance. That will be the vast majority to in-depth anxiety on the person and the family, and to reduce visits to the hospital, lab tests, some of them invasive.
And, on the other hand, to identify two monoclonal gammopathy of clinical significance. The first one is the one associated with transformation either to myeloma but also light chain amyloidosis also the former, particularly with waldenstrom macroglobulinemia.
And on the other hand, those gammopathy that may be associated with a higher risk of severe infection because infections are, according to, historical data. One of the reasons why MGUS may be associated with a slightly higher rate of morbidity and mortality.
So we believe that from the laboratory point of view, we now have the tools and didn't know how of creating a new model to identify these two monoclonal gammopathy of clinical significance so that the vast majority of cases will end up receiving a diagnosis that is not of undetermined. Its significance, rather, is of no clinical significance.
Keeping in mind that MGUS is a prevalence of more than 5% in individuals aged over 60, and we said enough is enough by 2030, such a high number of individuals in this aging population cannot be receiving a diagnosis of something of undetermined significance.
At ASH, we are showing, for example, how CTCs, circulating tumor cells that myeloma cell that leaves the marrow in circulating with peripheral blood is probably a missing element and a critical factor to stage these individuals.
If our videos have helped you in any way and you're able to, please consider making a donation to help us continue this important work. Your gift will go three times as far when we reach $500,000 by the end of the year. Every contribution, big or small, makes a difference and we're deeply grateful for your support.
HealthTree • December 18, 2025